Media coverage about Tetralogic Pharmaceuticals Corp (NASDAQ:TLOG) has been trending positive on Wednesday, Accern Sentiment Analysis reports. Accern identifies negative and positive press coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Tetralogic Pharmaceuticals Corp earned a news sentiment score of 0.37 on Accern’s scale. Accern also gave news headlines about the biopharmaceutical company an impact score of 46.0927054047168 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

Shares of Tetralogic Pharmaceuticals Corp (TLOG) opened at 0.0411 on Wednesday. The stock’s market cap is $1.02 million. The stock’s 50 day moving average is $0.02 and its 200-day moving average is $0.03. Tetralogic Pharmaceuticals Corp has a 12-month low of $0.02 and a 12-month high of $0.18.

COPYRIGHT VIOLATION WARNING: This article was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this article on another publication, it was copied illegally and republished in violation of United States and international copyright legislation. The original version of this article can be read at

Tetralogic Pharmaceuticals Corp Company Profile

TetraLogic Pharmaceuticals Corporation is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics in oncology, infectious diseases and autoimmune diseases. The Company’s segment is the identification and development of novel small molecule therapies in oncology and infectious diseases.

Insider Buying and Selling by Quarter for Tetralogic Pharmaceuticals Corp (NASDAQ:TLOG)

Receive News & Stock Ratings for Tetralogic Pharmaceuticals Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetralogic Pharmaceuticals Corp and related stocks with our FREE daily email newsletter.